Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

The Latest Advances on NEDD8 Inhibition for Treatment of Higher-Risk MDS and Other Hematologic Malignancies

Release Date: July 15, 2020
Expiration Date: July 15, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in MDS for an in-depth discussion covering key aspects of NEDD8 biology in cancer treatment and its potential impact in the treatment of MDS and other hematologic malignancies. The activity highlights the evolving role of the NEDD8 pathway and neddylation in cancer care, current challenges to diagnosis and risk stratification in MDS, and forecasts applications for novel NEDD8 inhibitors that address real-world clinical challenges.

This educational activity is an archive of the live virtual symposium held on June 25, 2020.

Acknowledgement of Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and hematologist/oncologists. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the mechanism of action of the NEDD8 pathway and its evolving role in hematologic malignancies
  • Explain the role of emerging NEDD8 inhibitors for the treatment of high-risk MDS and other hematologic malignancies
  • Consider patients who may be eligible for NEDD8 inhibitor treatment
  • Assess adverse events and management strategies associated with NEDD8 inhibitor treatment

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Amphivena, Helsinn, Celgene, Novartis, AbbVie, BMS, Astex, Onconova, H3Bio, Merck; Consultant: Astex, BMS, Helsinn.

Rami Komrokji, MD
Rami Komrokji, MD
Senior Member, Vice Chair
Section Head, Leukemia and MDS
Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: Acceleron, Agios, AbbVie, Celgene, DSI, Incyte, Pfizer, Jazz Pharma; Speakers Bureau: Agios, AbbVie, Jazz Pharma.

Jamile M. Shammo, MD, FASCP, FACP
Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Director of MDS/MPN/AA Program
Division of Hematology Oncology and Stem Cell Transplant
Rush University Medical Center
Chicago, IL

Disclosures: Grant Research Support: Onconova, Alexion, Celgene, CTI Pharma, Otsuka Pharmacuetical, Regenron; Consultant: Alexion, Celgene, Otsuka Pharmacuetical, Regenron, Novartis, BMS, Sanofi-Aventis; Speakers Bureau: Celgene, Incyte, Alexion, Sanofi; Other: AbbVie, Baxter.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By